Tag: Bexson Biomedical - Psychedelic Alpha

Our 2022 Year in Review is now live.

Read more about the article Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™

Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™

Post published:January 20, 2023
Post category:Press Release

Read more about the article Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award

Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award

Post published:October 20, 2022
Post category:Press Release

Read more about the article Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer ScD, Joins Its Scientific Advisory Board

Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer ScD, Joins Its Scientific Advisory Board

Post published:September 20, 2022
Post category:Press Release

Read more about the article Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SEVALENT™

Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SEVALENT™

Post published:September 15, 2022
Post category:Press Release

Read more about the article Bexson Biomedical Announces Participation in the Jeffries Innovation in Mental Health Summit

Bexson Biomedical Announces Participation in the Jeffries Innovation in Mental Health Summit

Post published:September 9, 2022
Post category:Press Release

Read more about the article Bexson Biomedical to present at the H.C. Wainwright and Beryl Elites Conferences

Bexson Biomedical to present at the H.C. Wainwright and Beryl Elites Conferences

Post published:June 17, 2022
Post category:Press Release

Read more about the article Bexson Biomedical Launches New Project, Applying Subcutaneous Delivery Technology To Multiple Psychedelic Compounds For Therapeutic Use

Bexson Biomedical Launches New Project, Applying Subcutaneous Delivery Technology To Multiple Psychedelic Compounds For Therapeutic Use

Post published:August 12, 2021
Post category:Press Release

Read more about the article Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation

Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation

Post published:April 29, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.